Luye Pharma Group Ltd
Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and X… Read more
Luye Pharma Group Ltd (LYPHF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.108x
Based on the latest financial reports, Luye Pharma Group Ltd (LYPHF) has a cash flow conversion efficiency ratio of 0.108x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.78 Billion) by net assets ($16.54 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Luye Pharma Group Ltd - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how Luye Pharma Group Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Luye Pharma Group Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Luye Pharma Group Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cohort plc
F:C7K
|
0.067x |
|
Shenzhen Sunwin Intelligent
SHE:300044
|
-0.017x |
|
Hyosung TNC Corp
KO:298020
|
0.097x |
|
Oneness Biotech Co Ltd
TWO:4743
|
0.001x |
|
MNC Studios International Tbk PT
JK:MSIN
|
0.027x |
|
Wuxi Hodgen Technology Co Ltd
SHE:300279
|
-0.006x |
|
Malaysian Pacific Industries
KLSE:3867
|
0.070x |
|
Yunding Technology Co Ltd
SHE:000409
|
-0.043x |
Annual Cash Flow Conversion Efficiency for Luye Pharma Group Ltd (2003–2024)
The table below shows the annual cash flow conversion efficiency of Luye Pharma Group Ltd from 2003 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $15.75 Billion | $167.76 Million | 0.011x | -90.97% |
| 2023-12-31 | $13.53 Billion | $1.60 Billion | 0.118x | -21.26% |
| 2022-12-31 | $11.04 Billion | $1.65 Billion | 0.150x | +648.50% |
| 2021-12-31 | $9.11 Billion | $182.37 Million | 0.020x | -84.32% |
| 2020-12-31 | $8.10 Billion | $1.03 Billion | 0.128x | -31.47% |
| 2019-12-31 | $9.37 Billion | $1.74 Billion | 0.186x | +41.28% |
| 2018-12-31 | $7.93 Billion | $1.05 Billion | 0.132x | -5.74% |
| 2017-12-31 | $6.90 Billion | $964.10 Million | 0.140x | +54.96% |
| 2016-12-31 | $6.56 Billion | $592.03 Million | 0.090x | +32.56% |
| 2015-12-31 | $5.80 Billion | $394.71 Million | 0.068x | +7.44% |
| 2014-12-31 | $5.04 Billion | $319.10 Million | 0.063x | -72.59% |
| 2013-12-31 | $1.90 Billion | $438.62 Million | 0.231x | +139.41% |
| 2012-12-31 | $1.58 Billion | $152.90 Million | 0.097x | -58.29% |
| 2011-12-31 | $1.40 Billion | $325.02 Million | 0.231x | +13.63% |
| 2010-12-31 | $1.25 Billion | $254.21 Million | 0.204x | +36.65% |
| 2009-12-31 | $1.09 Billion | $163.16 Million | 0.149x | +15.66% |
| 2008-12-31 | $821.86 Million | $105.90 Million | 0.129x | -27.75% |
| 2007-12-31 | $776.55 Million | $138.51 Million | 0.178x | +154.64% |
| 2006-12-31 | $728.12 Million | $51.00 Million | 0.070x | -42.90% |
| 2005-12-31 | $349.51 Million | $42.87 Million | 0.123x | -27.57% |
| 2004-12-31 | $283.38 Million | $47.99 Million | 0.169x | -56.68% |
| 2003-12-31 | $103.17 Million | $40.33 Million | 0.391x | -- |